TESARO Inc (TSRO) : Simplex Trading added new position in TESARO Inc during the most recent quarter end. The investment management firm now holds 9,616 shares of TESARO Inc which is valued at $954,484 , the company said in a statement filed on Oct 7, 2016 with the SEC.TESARO Inc makes up approximately 0.12% of Simplex Trading’s portfolio.
Other Hedge Funds, Including , First Mercantile Trust Co reduced its stake in TSRO by selling 1,010 shares or 26.65% in the most recent quarter. The Hedge Fund company now holds 2,780 shares of TSRO which is valued at $275,943. TESARO Inc makes up approx 0.04% of First Mercantile Trust Co’s portfolio.Bnp Paribas Arbitrage Sa reduced its stake in TSRO by selling 8,903 shares or 79.51% in the most recent quarter. The Hedge Fund company now holds 2,295 shares of TSRO which is valued at $234,870.
TESARO Inc closed down -0.63 points or -0.63% at $99.26 with 13,64,709 shares getting traded on Friday. Post opening the session at $100.21, the shares hit an intraday low of $96.52 and an intraday high of $101.6 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, TESARO Inc reported $-1.28 EPS for the quarter, beating the analyst consensus estimate by $ 0.42 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-1.70. The company had revenue of $36.60 million for the quarter, compared to analysts expectations of $2.48 million. During the same quarter in the previous year, the company posted $-1.51 EPS.
Many Wall Street Analysts have commented on TESARO Inc. Company shares were Reiterated by RBC Capital Mkts on Oct 10, 2016 to “Outperform”, Firm has raised the Price Target to $ 128 from a previous price target of $122 .Company shares were Reiterated by Wedbush on Oct 10, 2016 to “Outperform”, Firm has raised the Price Target to $ 139 from a previous price target of $107 .TESARO Inc was Upgraded by BofA/Merrill to ” Buy” on Oct 10, 2016.
TESARO Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates rolapitant niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1 or NK-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib formerly known as MK-4827 is an orally active and potent poly (ADP-ribose) polymerase and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio Inc. for the discovery and development of antibodies for several specified immuno-oncology targets.